Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

American journal of respiratory and critical care medicine·2026

Same author

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.

Thoracic cancer·2026

Same author

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Respiratory medicine·2026

Search research articles

Related Experiment Video

Updated: Oct 15, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.

Kei Kunimasa¹, Takahisa Kawamura¹, Motohiro Tamiya¹

¹Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Thoracic Cancer

|October 25, 2021

Summary

Tepotinib caused severe peripheral edema, but switching to capmatinib allowed continued treatment for metastatic non-small cell lung cancer with MET exon 14 skipping. This case highlights differing side effect profiles of MET inhibitors.

Keywords:

MET ex.14 skipping capmatinib peripheral edema tepotinib

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Experiment Videos

Last Updated: Oct 15, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Area of Science:

Oncology
Pharmacology

Background:

Capmatinib and tepotinib are FDA-approved MET inhibitors for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping.
Peripheral edema is a common adverse event associated with both capmatinib and tepotinib treatment.

Observation:

A patient experienced intolerable peripheral edema while receiving tepotinib.
The patient was successfully switched to capmatinib, allowing for continued treatment of their metastatic NSCLC.

Findings:

This case report is the first to demonstrate differential effects of two MET inhibitors, tepotinib and capmatinib, on the development of peripheral edema.
Switching between these MET inhibitors may be a viable strategy to manage treatment-related peripheral edema.

Implications:

This finding suggests that individual patient tolerance to specific MET inhibitors can vary regarding peripheral edema.
Management strategies for peripheral edema in patients receiving MET inhibitors may involve drug switching.
Further research is warranted to understand the mechanisms behind differential peripheral edema development and to establish unified management guidelines.